Rut Valgardsdottir
Overview
Explore the profile of Rut Valgardsdottir including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
486
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zaninelli S, Panna S, Tettamanti S, Melita G, Doni A, DAutilia F, et al.
Antibodies (Basel)
. 2024 Sep;
13(3).
PMID: 39311376
Strategies to increase the anti-tumor efficacy of cytokine-induced killer cells (CIKs) include genetic modification with chimeric antigen receptors (CARs) or the addition of soluble T-cell engaging bispecific antibodies (BsAbs). Here,...
2.
Cattaneo I, Choblet S, Valgardsdottir R, Roth M, Massafra A, Beeg M, et al.
Antibodies (Basel)
. 2024 Feb;
13(1).
PMID: 38390876
We designed, produced, and purified a novel IgG1-like, bispecific antibody (bsAb) directed against B-cell maturation antigen (BCMA), expressed by multiple myeloma (MM) cells, and an immune checkpoint inhibitor (ICI), PDL1,...
3.
Cattaneo I, Valgardsdottir R, Cavagna R, Spinelli O, Bartoletti-Stella A, Capellari S, et al.
Br J Haematol
. 2023 Nov;
204(2):571-575.
PMID: 37957838
Multiple myeloma (MM) cells from 1 out of 20 patient expressed high basal levels of membrane B-cell maturation antigen (BCMA, TNFRSF17, CD269), which was not upregulated by gamma-secretase inhibitor, suggesting...
4.
Interdonato A, Choblet S, Sana M, Valgardsdottir R, Cribioli S, Alzani R, et al.
Cytotherapy
. 2021 Sep;
24(2):161-171.
PMID: 34538717
Background Aims: The authors describe here a novel therapeutic strategy combining a bispecific antibody (bsAb) with cytokine-induced killer (CIK) cells. Methods: The authors have designed, produced and purified a novel...
5.
Valgardsdottir R, Cattaneo I, Napolitano G, Raglio A, Spinelli O, Salmoiraghi S, et al.
Antibodies (Basel)
. 2021 Jul;
10(3).
PMID: 34287229
We report the isolation of two human IgG1k monoclonal antibodies (mAbs) directed against the SARS-CoV-2 spike protein. These mAbs were isolated from two donors who had recovered from COVID-19 infection...
6.
Golay J, Valgardsdottir R, Musaraj G, Giupponi D, Spinelli O, Introna M
Blood
. 2019 Jan;
133(13):1395-1405.
PMID: 30655272
We have identified a rare healthy FcγRIIIB (CD16B)-null donor completely lacking FCGR3B RNA and protein expression and dissected the role of the different neutrophil Fcγ receptors in the response to...
7.
Introna M, Lussana F, Algarotti A, Gotti E, Valgardsdottir R, Mico C, et al.
Biol Blood Marrow Transplant
. 2017 Jul;
23(12):2070-2078.
PMID: 28712935
Seventy-four patients who relapsed after allogeneic stem cell transplantation were enrolled in a phase IIA study and treated with the sequential infusion of donor lymphocyte infusion (DLI) followed by cytokine-induced...
8.
Valgardsdottir R, Cattaneo I, Klein C, Introna M, Figliuzzi M, Golay J
Blood
. 2017 Mar;
129(19):2636-2644.
PMID: 28288980
Polymorphonuclear neutrophils (PMNs) have previously been reported to mediate phagocytosis of anti-CD20-opsonized B cells from patients with chronic lymphocytic leukemia (CLL). However, recent data have suggested that PMNs, like macrophages,...
9.
Golay J, DAmico A, Borleri G, Bonzi M, Valgardsdottir R, Alzani R, et al.
J Immunol
. 2014 Oct;
193(9):4739-47.
PMID: 25267972
Current treatment of chronic lymphocytic leukemia (CLL) patients often results in life-threatening immunosuppression. Furthermore, CLL is still an incurable disease due to the persistence of residual leukemic cells. These patients...
10.
Valgardsdottir R, Capitanio C, Texido G, Pende D, Cantoni C, Pesenti E, et al.
Exp Hematol
. 2014 Sep;
42(12):1013-21.e1.
PMID: 25201755
Cytokine-induced killer (CIK) cells are in-vitro-expanded T lymphocytes that represent a heterogeneous population. A large majority of CIK cells are CD3(+)CD56(+), and this population has been shown to confer a...